# A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease

> **NCT07284381** · PHASE3 · RECRUITING · sponsor: **AbbVie** · enrollment: 250 (estimated)

## Conditions studied

- Dry Eye Disease

## Interventions

- **DRUG:** ABBV-444
- **DRUG:** REFRESH OPTIVE UD

## Key facts

- **NCT ID:** NCT07284381
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-15
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07284381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07284381, "A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT07284381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*